Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 6kWORD 29k
5 June 2018
Answer given by Mr Moedas on behalf of the Commission
Question reference: E-001327/2018

1. Vaccines may contain small amounts of aluminium acting as adjuvants. They are authorised nationally or centrally. The European Medicine Agency (EMA)(1) is in contact with the French National Agency for Medicines and Health Products Safety (ANMS), which financed the research referred to by the Honourable Member. In September 2017, ANMS communicated that the results of the new studies, as well as the available publication, do not change the positive benefit/risk ratio of vaccines(2). EMA, in collaboration with the EU Member States, continuously monitors the safety of aluminium-containing vaccines, including studies reported in the worldwide scientific literature, and will take any necessary action in case a safety issue is identified.

2. Through the Innovative Medicines Initiative (IMI),(3) the Commission funds research on vaccine safety. The IMI projects ADVANCE(4) and BioVacSafe(5) work to deliver reliable data on the benefits/risks of marketed vaccines, and to improve testing and monitoring of vaccine safety, respectively.

(4)ADVANCE, http://www.advance-vaccines.eu/
(5)BioVacSafe, http://www.biovacsafe.eu/

Last updated: 6 June 2018Legal notice